Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706638 | 1.00 | NCF1 (0.35) | NCF1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL17126989 | 1.00 | NCF1 (0.35) | NCF1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL9909907 | 0.84 | GNAI3 (0.33) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL17126993 | 0.84 | GNAI3 (0.33) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL15490079 | 0.84 | GNAI3 (0.33) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL17127007 | 0.81 | GNAI3 (0.40) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL15490077 | 0.81 | GNAI3 (0.40) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL9909914 | 0.78 | GNAI3 (0.42) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL15490082 | 0.78 | GNAI3 (0.42) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL17126995 | 0.76 | NCF1 (0.42) | NCF1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GCGR, GPR139 | NCF1 3873/4885GNAI3 229/4885GNAO1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.